A prescriber can consider switching from tirzepatide to semaglutide when semaglutide is appropriate for the condition being treated. The U.S. Wegovy and Zepbound labels advise against combining them with other GLP-1 medicines. Ask your prescriber to plan the change [4] [5].
What direct evidence on the switch shows
The evidence on switching from semaglutide to tirzepatide includes different patients and study designs. In one report on the reverse switch, a 40-year-old man with obesity lost less than 5% of his weight during six months of tirzepatide treatment. His weight went from 115 kg at baseline to 109.5 kg before switching and 92 kg six months after starting semaglutide. The 20% figure measures total loss from his original baseline [1].
A UK service reported at the 2026 UK Congress on Obesity that it switched 3,291 patients from tirzepatide to semaglutide. It reviewed reports of potentially significant side effects over a short period. The abstract did not report weight outcomes after switching or estimate a comparative safety effect [2].
What the head-to-head trial measured
In SURMOUNT-5, adults with obesity and without type 2 diabetes were assigned to tirzepatide or semaglutide. Estimated average weight loss at week 72 was 20.2% with tirzepatide compared with 13.7% with semaglutide. Those figures come from separate randomized groups. The trial did not measure weight after changing from tirzepatide to semaglutide[3].
What to discuss with your prescriber
The monthly GLP-1 cost guide explains how cash prices, coverage and drug formulation affect the bill. Bring information about why you want to switch and how you responded to your current medicine so the prescriber can weigh treatment options.